Gastroenterology. 2010 Jul 13. [Epub ahead of print]
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A, Connell EV, Diago M.
University of Calgary, Health Research Innovation Center, Calgary, Alberta, Canada.
BACKGROUND & AIMS:
A sustained virologic response (SVR) to therapy for Hepatitis C virus (HCV) infection is defined as the inability to detect HCV RNA 24 weeks after treatment has been completed. Although small studies have reported that the SVR is durable and lasts for long time periods, it has not been conclusively demonstrated in larger studies.
The durability of treatment responses were examined in patients who were originally enrolled in 1 of 9 randomized, multicenter trials (n=1343 patients). The study included patients who received peginterferon alfa-2a alone (n=166 patients) or in combination with ribavirin (n=1077 paients), including 79 patients with normal levels of alanine aminotransferase and 100 patients that were co-infected with HIV and HCV) and whose serum samples were negative for HCV RNA (